January 14th 2025
Lonza will develop spray-dried formulations for an intranasally delivered biologic using a reformulated biologic drug candidate for obesity in Iconovo’s pipeline.
Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.